• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Nabi Biopharmaceuticals to Announce Second Quarter 2005 Financial Results on July 19, 2005

Posted on: Wednesday, 6 July 2005, 09:01 CDT

BOCA RATON, Fla., July 6 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals will issue a press release highlighting the second quarter financial results on Tuesday, July 19, 2005, at market close. The company will also host a live webcast and audio conference call at 4:30 p.m. ET. Nabi Biopharmaceuticals' management will discuss the second quarter results and expectations.

The live webcast can be accessed at: http://audioevent.mshow.com/245334 or via the Nabi Biopharmaceuticals website at http://www.nabi.com/ . If you do not have internet access, the domestic call-in number is 877-569-0953, conference code 7442676 and the international call-in number is 706-634-4967, conference code 7442676. An audio replay will be available for domestic callers at 800-642-1687, conference code 7442676, and for international callers at 706-645-9291, conference code 7442676.

Following the webcast, an archived version of the webcast will be available at the same internet address through July 26, 2005. The audio replay will also be available through July 26, 2005. The press release will be available on the company's website at: http://www.nabi.com/ .

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are poised to capture large, commercial opportunities in our four core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and preclinical development. The company filed its Marketing Authorization Application in Europe for its candidate product StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate Vaccine] in December 2004. The application was accepted for review in January 2005. StaphVAX is currently in a confirmatory Phase III clinical trial in the United States. StaphVAX is designed to prevent the most dangerous and prevalent strains of Staphylococcus aureus bacterial infections. S. aureus bacteria are a major cause of hospital-acquired infections and are becoming increasingly resistant to antibiotics. The company's other products in development include Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)], an antibody for prevention and treatment of S. aureus infections, NicVAX(TM) [Nicotine Conjugate Vaccine], a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website at: http://www.nabi.com/ .

Audio: http://audioevent.mshow.com/245334

Nabi Biopharmaceuticals

CONTACT: Constance Bienfait, Vice President, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800

Web site: http://www.nabi.com/

Source: PRNewswire-FirstCall

More News in this Category